Montreal, Quebec, Canada, September 14, 2011– Jubilant HollisterStier Contract Manufacturing announced today that their Montreal-based facility has entered into a four year contract to manufacture a leading over the counter (OTC) prescription-strength treatment product with the total revenue being over $70M during that time period.
 
“We have successfully helped provide safe and effective products to consumers over the course of many years and look forward to continuing to do so for this product.  The addition to our globally leading OCL (ointment, creams, liquids) capabilities is a further strength of our strategy to expand our offering across products and geographies.” said Marcelo Morales, Chief Executive Officer, Jubilant HollisterStier, Contract Manufacturing & Services.”

About Jubilant HollisterStier
Jubilant HollisterStier is a subsidiary of Jubilant Life Sciences, an integrated pharma and life sciences company headquartered in India. Through its Contract Manufacturing & Services division it provides its customers global manufacturing services to aseptically fill liquid and lyophilized products as well as semi-solid and solid dosage forms at its facilities in the United States, Canada, and India. Jubilant HollisterStier offers highly-skilled, cross-functional teams to provide custom solutions to customer-specific project goals from development through commercialization. Jubilant HollisterStier is committed to providing exceptional quality, regulatory expertise and operational excellence to ensure streamlined processes and services in all facilities.  For more info about Jubilant HollisterStier, visit jublHS.com.

About Jubilant Life Sciences
Jubilant Life Sciences Limited, is an integrated Pharma and Life Sciences Company.  It is the largest Custom Research and Manufacturing Services (CRAMS) Company and a leading Drug Discovery & Development Solutions provider out of India. The Company provides Life Sciences products and services across the value chain.  With 10 world-class manufacturing facilities and a team of ~5800 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 75 countries. The Company is well recognized as a “Partner of Choice” by leading life sciences companies worldwide. Its revenues for FY 2011 stood at  US$ 770 Mn.  For more info: www.jubl.com

 Media Inquiries
Shannon Jordan, 509.482.4958
 
Disclaimer
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences and its subsidiaries may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company’s filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.